Heterocyclic and phenyl double-bond-locked combretastatin analogues possessing potent apoptosis-inducing activity in HL60 and in MDR cell lines

Journal of Medicinal Chemistry

Volumn 48, Issue 3, 2005, Pages 723-736

  Simoni, Daniele ^a   Grisolia, Giuseppina ^a   Giannini, Giuseppe ^b   Roberti, Marinella ^c   Rondanin, Riccardo ^a   Piccagli, Laura ^a   Baruchello, Riccardo ^a   Rossi, Marcello ^a   Romagnoli, Romeo ^a   Invidiata, Francesco Paolo ^d   Grimaudo, Stefania ^e   Jung, M Katherine ^f   Hamel, Ernest ^g   Gebbia, Nicola ^d   Crosta, Lucia ^d   Abbadessa, Vincenzo ^e   Di Cristina, Antonietta ^e   Dusonchet, Luisa ^d   Meli, Maria ^d   Tolomeo, Manlio ^e  

^a UNIVERSITY OF FERRARA   (Italy)

^b R and D   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e Policlinico di Palermo   (Italy)

^f SAIC FREDERICK INC   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)PYRIDIN 3 YL]PHENOL; 2 METHOXY 5 [3 METHOXY 4 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDROISOXAZOL 5 YL]PHENOL; 2 METHOXY 5 [3 METHOXY 5 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDROISOXAZOL 4 YL]PHENOL; 5 [3 BENZENESULFONYL 4 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDROISOXAZOL 5 YL] 2 METHOXYPHENOL; 5 [5 CHLORO 2 (3,4,5 TRIMETHOXYPHENYL)PYRIDIN 3 YL] 2 METHOXYPHENOL; BENZENE; COMBRETASTATIN A4; HETEROCYCLIC COMPOUND; ISOXAZOLINE DERIVATIVE; PHENYL GROUP; PYRIDINE; TUBULIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL STRAIN HL 60; CHEMICAL BOND; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFECT; DRUG POTENCY; HUMAN; HUMAN CELL; IC 50; MITOSIS INHIBITION; PROTEIN MOTIF; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENE DERIVATIVES; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; ISOXAZOLES; MODELS, MOLECULAR; PYRIDINES; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 13444267332     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049622b     Document Type: Article

References (44)

1. Kaufmann, S. H.; Hengartner, M. O. Programmed cell death: alive and well in the new millennium. Trends Cell Biol. 2001, 11, 526-34.
2. Tolomeo, M.; Simoni, D. Drug resistance and apoptosis in cancer treatnent: Development of new apoptosis-inducing agents active in drug resistant malignancies. Curr. Med. Chem: Anti-Cancer Agents 2002, 2, 387-401.
3. Kasibhatla, S.; Tseng, B. Why target apoptosis in cancer treatment? Mol. Cancer Ther. 2003, 2, 573-580.
4. Zhivotovsky, B.; Orrenius, S. Defects in apoptotic machinery of cancer cells: role in drug resistance. Semin. Cancer Biol. 2000, 13, 125-134.
5. Igney, F. K.; Krammer, P. H. Death and anti-death: tumor resistance to apoptosis. Nat. Rev. Cancer 2002, 2, 277-288.
6. Mollinedo, F. Gajate, C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003, 8, 413-450.
7. Simoni, D.; Tolomeo, M. Retinoids, Apoptosis and cancer. Curr. Pharm. Des. 2001, 7, 1823-1837 and references therein.
8. Pettit G. R, Cragg G. M, Singh S. B. Antineoplastic agents, 122: constituents of Combretum caffrum. J. Nat. Prod. 1987, 50: 386-391.
9. Pettit G. R.; Cragg G. M.; Herald D. L.; Schmidt J. M.; Lobavanijaya P. Isolation and structure of combretastatin. Can. J. Chem. 1982, 60, 1347-1376.
10. Boye, O.; Brossi, A. In The Alkaloids; Brossi, A., Cordell, G. A., Eds.; Academic: New York, 1992; Vol. 41, pp 125-178.
11. Lin, C. M.; Singh, S. B.; Chu, P. S.; Dempcy, R. O.; Schmidt, J. M.; Pettit, G. R.; Hamel, E. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol. Pharmacol. 1988, 34, 200-208.
12. Lin, C. M.; Ho, H. H.; Pettit, G. R. Antimitotic natural products combretastatin A-4 and combretastatin A-2: Studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 1989, 28, 6984-6991.
13. Pettit, G. R.; Singh, S. B. Isolation, structure, and synthesis of combretastatin A-2, A-3, and B-2. Can. J. Chem. 1987, 65, 2390-2396.
14. Pettit, G. R.; Temple, C. Jr.; Narayanan, V. L.; Varma, R.; Simpson, M. J.; Boyd, M. R.; Rener, G. A.; Bansal, N. Antineoplastic Agents 322. Synthesis of Combretsstatin A-4 Prodrugs. Anti-Cancer Drug Des. 1995, 10, 299-309.
15. Hamel E, Lin C. M. Interactions of combretastatin, a new plant-derived antimitotic agent with tubulin. Biochem. Pharmacol. 1983, 32, 3864-3867.
16. Pettit G. R.; Singh S. B.; Hamel E.; Lin C. M.; Alberts D. S.; Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989, 45, 209-211.
17. McGown A. T.; Fox B. W. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A-4 and amphethinile. Anti-cancer Drug Des. 1989, 3, 249-254.
18. Nam, N. H. Combretastatin A-4 analogues as antimitotic antitumor agents. Curr. Med. Chem. 2003, 10, 1697-1722.
19. Hamel, E. In Microtubule Proteins; Avila, J., Ed.; CRC Press: Boca Raton, FL, 1990; pp 89-191.
20. Xia, Y.; Yang, Z.-Y.; Xia, P.; Bastow, K. F.; Tachibana, Y.; Kuo, S.-C.; Hamel, E.; Hackl, T.; Lee, K.-H. Antitumor agents. 181. Synthesis and biological evaluation of 6, 7, 2′, 3′, 4′-substituted-1,2,3,4- tetrahydro-2-phenyl-4-quinolones as a new class of antimitotic antitumor agents. J. Med. Chem. 1998, 41, 1155-1162.
21. Pettit, G. R.; Lippert, J. W., III.; Herald, D. L.; Hamel, E.; Pittit, R. K. Antineoplastic agents 440. Asymmetric synthesis and evaluation of the combretastatin A-1 SAR probes (1S, 2S)- and (1R, 2R)-1,2-dihydroxy-1-(2′, 3″-dihydroxy-4′-methoxyphenyl)-2-(3″, 4″, 5″-trimethoxyphenyl) ethane. J. Nat. Prod. 2000, 63, 969-974.
22. Chaplin, D. J.; Pettit, G. R.; Parkins, C. S.; Hill, S. A.; Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br. J. Cancer 1996, 27, S86-88.
23. Chaplin D. J.; Pettit G. R.; Hill S. A. Anti-vascular approaches to solid tumor therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. 1999, 19, 189-195.
24. Nabha S. M.; Mohammed R. M.; Dandashi M. H.; Coupaye-Gerard B.; Aboukameel A.; Petit G. R.; Al-Katib A. M. Comretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clin. Cancer Res. 2002, 8, 2733-2741.
25. Simoni, D.; Roberti, M.; Invidiata, F. P.; Rondanin, R.; Baruchello, R.; Malagutti, C.; Mazzali, A.; Rossi, M.; Grimaudo, S.; Dusonchet, L.; Meli, M.; Raimondi, M. V.; D'Alessandro, N.; Tolomeo, M. Programmed cell death (PCD) associated with the stilbene motif of arotinoids: Discovery of novel apoptosis inducer agents possessing activity on multidrug resistant tumor cells. Bioorg. Med. Chem. Lett. 2000, 10, 2669-2673.
26. Simoni, D.; Roberti, M.; Invidiata, F. P.; Rondanin, R.; Baruchello, R.; Malagutti, C.; Mazzali, A.; Rossi, M.; Grimaudo, S.; Capone, F.; Dusonchet, L.; Meli, M.; Raimondi, M. V., Landino, M.; D'Alessandro, N.; Tolomeo, M.; Arindam, D.; Lu, S.; Benbrook, D. M. Heterocycle-containing retinoids. Discovery of a novel isoxazole arotinoid possessing potent apoptotic activity in multidrug and drug-induced apoptosis-resistant cells. J. Med. Chem. 2001, 44, 2308-2318.
27. Grimaudo, S.; Tolomeo, M.; Capone, F.; Pagliaro, M.; Rondanin, R.; Baruchello, R.; Simoni, D.; Mariani, G. Effects of AC7739, a water-soluble amino derivative of combretastatin A-4, in multidrug-resistant and apoptosis-resistant leukemia cell lines. Blood 2001, 98, 445.
28. Roberti, M.; Pizzirani, D.; Simoni, D.; Rondanin, R.; Baruchello, R.; Bonora, C.; Buscemi, F.; Grimaudo, S.; Tolomeo, M. Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents. J. Med. Chem. 2003, 46, 3546-3554.
29. Simoni, D.; Giannini, G.; Baraldi, P. G.; Romagnoli, R.; Roberti, M.; Rondanin, R.; Baruchello, R.; Grisolia, G.; Rossi, M.; Mirizzi, D.; Invidiata, F. P.; Grimaudo, S.; Tolomeo, M. A convenient synthesis of unsymmetrically substituted terphenyls of biologically active stilbenes via a double Suzuki cross-coupling protocol. Tetrahedron Lett. 2003, 44, 3005-3008
30. Pettit, G. R.; Singh, S. B.; Cragg, G. M. Synthesis of natural (-)-combretastatin. J. Org. Chem. 1985, 50, 3404-3406.
31. Larsen, K. E.; Torssell K. B. G. An improved procedure for the preparation of 2-isoxazolines. Tetrahedron 1984, 40, 2985-2988.
32. Wade, P. A.; Amin, V. N.; Yen, H.-K.; Price, T. D.; Huhn, G. F. Acid-catalyzed nitronate cycloaddition reactions. Useful syntheses and simple transformations of 3-acyl- and 3- alkenylisoxazolines. J. Org. Chem. 1984, 49, 4595-4601.
33. Miyaura, N.; Suzuki, N. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 1995, 95, 2457-2483.
34. Nair, V.; Cooper, C. S. Chemistry of 1,5-diazapentadienium (vinamidinium) salts: alkilation reactions to multifunctional dienamines and diaminones. J. Org. Chem. 1981, 46, 4759-4765.
35. Davies, I. W.; Marcoux, J.-F.; Wu, J.; Palucki, M.; Corley, E. G.; Robbins, M. A.; Tsou, N.; Ball, R. G.; Dormer, P.; Larsen, R. D.; Reider, P. J. An efficient preparation of vinamidinium hexafluorophosphate salt. J. Org. Chem. 2000, 65, 4571-4574.
36. Wang, L.; Woods, K. W.; Li, Q.; Barr, K. J.; McCroskey, R. W.; Hannick, S. M.; Gherke, L.; Credo, R. B.; Hui, Y. A.; Marsh, K.; Warner, R.; Lee, J. Y.; Zielinski-Mozng, N.; Frost, D.; Rosenberg, S. H.; Sham, H. L. Potent, orally active heterocycle-based combretastatin A-4 analogues: Synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J. Med. Chem. 2002, 45, 1697-1711.
37. Nam, N.-H.; Kim, Y.; You, Y.-J.; Hong, D.-H.; Kim, H.-M.; Ahn, B.-Z. Combretoxazolones: Synthesis, cytotoxicity and antitumor activity. Bioorg. Med. Chem. Lett. 2001, 11, 3073-3076.
38. Nam, N.-H.; Kim, Y.; You, Y.-J.; Hong, D.-H.; Kim, H.-M.; Ahn, B.-Z. Synthesis and anti-tumor activity of novel combretastatins: Combretocyclopentenones and related analogues. Bioorg. Med. Chem. Lett. 2002, 12, 1955-1958.
39. Szczepankiewicz, B. G.; Liu, G.; Jae, H.-S.; Tasker, A. S.; Gunawardana, I. W.; von Geldern, T. W.; Gwaltney, II, S. L.; Wu-Wong, J. R.; Gehrke, L.; Chiou, W. J.; Credo, R. B.; Alder, J. D.; Nukkala, M. A.; Zielinski, N. A.; Jarvis, K.; Mollison, K. W.; Frost, D. J.; Bauch, J. L.; Hua Hui, Y.; Claiborne, A. K.; Li, Q.; Rosenberg, S. H. New antimitotic agents with activity in multi-drug-resistant cell lines and in vivo efficacy in murine tumor models. J. Med. Chem. 2001, 44, 4416-4430.
40. Hamel, E. Evaluation of antimitotic agents by quantitative comparison of their effects on the polymerization of purified tubulin. Cell Biochem. Biophys. 2003, 38, 1-21.
41. Verdier-Pinard, P.; Lai, J. Y.; Yoo, H. D.; Yu, J.; Marquez, B.; Nagle, D. G.; Nambu, M.; White, J. D.; Falck, J. R.; Gerwick, W. H.; Day, B. W.; Hamel, E. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol. Pharmacol. 1998, 53, 62-76.
42. Hamel, E.; Lin, C. M. Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles. Biochemistry 1984, 23, 4173-4184.
43. Dewar, M. J. S. E.; Zoebish, G.; Healy, E. F. AM1: A new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
44. Mohamadi F.; Richards N. G. J.; Guida W. C.; Liscamp R.; Lipton M.; Caufield C.; Chang G.; Hendrickson T.; Still W. C. Macromodel - An integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 1990, 11, 440-450.